Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2005 1
2006 2
2009 3
2010 2
2011 3
2012 5
2013 3
2014 6
2015 4
2016 3
2017 5
2018 7
2019 4
2020 6
2021 4
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Metronomic Chemotherapy in Elderly Patients.
Bandini A, Calabrò PF, Banchi M, Orlandi P, Bocci G. Bandini A, et al. Among authors: orlandi p. Curr Oncol Rep. 2024 Apr;26(4):359-376. doi: 10.1007/s11912-024-01505-w. Epub 2024 Mar 7. Curr Oncol Rep. 2024. PMID: 38448722 Free PMC article. Review.
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effects.
Robello M, Salerno S, Barresi E, Orlandi P, Vaglini F, Banchi M, Simorini F, Baglini E, Poggetti V, Taliani S, Da Settimo F, Bocci G. Robello M, et al. Among authors: orlandi p. Arch Pharm (Weinheim). 2022 Nov;355(11):e2200295. doi: 10.1002/ardp.202200295. Epub 2022 Jul 29. Arch Pharm (Weinheim). 2022. PMID: 35904260
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.
Orlandi P, Banchi M, Vaglini F, Carli M, Aringhieri S, Bandini A, Pardini C, Viaggi C, Lai M, Alì G, Ottani A, Vandini E, Guidi P, Bernardeschi M, La Rocca V, Francia G, Fontanini G, Pistello M, Frenzilli G, Giuliani D, Scarselli M, Bocci G. Orlandi P, et al. Biochem Pharmacol. 2024 Jan;219:115952. doi: 10.1016/j.bcp.2023.115952. Epub 2023 Nov 29. Biochem Pharmacol. 2024. PMID: 38036189 Free article.
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, Di Desidero T, Orlandi P, Bocci G. Lazzeri S, et al. Among authors: orlandi p. Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7. Angiogenesis. 2015. PMID: 26346237 Review.
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, Scalese M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G, Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D, Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. Coltelli L, et al. Among authors: orlandi p. NPJ Breast Cancer. 2022 Mar 21;8(1):33. doi: 10.1038/s41523-022-00400-6. NPJ Breast Cancer. 2022. PMID: 35314692 Free PMC article.
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
Pasqualetti F, Gonnelli A, Orlandi P, Palladino E, Giannini N, Gadducci G, Mattioni R, Montrone S, Calistri E, Mazzanti CM, Franceschi S, Ortenzi V, Scatena C, Zavaglia K, Fanelli GN, Morganti R, Santonocito O, Bocci G, Naccarato GA, Paiar F. Pasqualetti F, et al. Among authors: orlandi p. Invest New Drugs. 2021 Aug;39(4):1159-1165. doi: 10.1007/s10637-021-01075-9. Epub 2021 Feb 8. Invest New Drugs. 2021. PMID: 33558989
62 results